Alumis Inc. (ALMS) — SEC Filings
Alumis Inc. (ALMS) — 34 SEC filings. Latest: 8-K (Mar 30, 2026). Includes 18 8-K, 5 10-Q, 3 SC 13D.
Overview
Alumis Inc. (ALMS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 30, 2026: Alumis Inc. filed an 8-K on March 30, 2026, reporting other events and financial statements. The filing includes various exhibits, such as graphics, indicating potential updates or disclosures related to the company's operations or financial performance.
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 1 bearish, 31 neutral, 2 mixed. The dominant filing sentiment for Alumis Inc. is neutral.
Filing Type Overview
Alumis Inc. (ALMS) has filed 18 8-K, 5 10-Q, 1 8-K/A, 1 DEF 14A, 1 10-K/A, 1 10-K, 3 SC 13D, 1 SC 13G, 2 S-1/A, 1 S-1 with the SEC between Jun 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of ALMS's 33 recent filings, 2 were flagged as high-risk, 16 as medium-risk, and 15 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $22.12M |
| Net Income | -$150.39M |
| EPS | N/A |
| Debt-to-Equity | 0.27 |
| Cash Position | $65.26M |
| Operating Margin | N/A |
| Total Assets | $488.01M |
| Total Debt | $103.24M |
Key Executives
- Board of Directors
- Audit Committee
- Abrar Hussain
- James B. Tananbaum
- Gregory A. Brown
- Eleazer Klein, Esq.
- Adriana Schwartz, Esq.
- Martin Babler
Industry Context
Alumis operates in the highly competitive biotechnology sector, focusing on developing therapies for autoimmune and inflammatory diseases. The industry is characterized by significant R&D investment, long development cycles, and high regulatory hurdles. Success hinges on clinical trial outcomes, regulatory approvals, and effective market penetration against established and emerging competitors.
Top Tags
financials (8) · pharmaceuticals (7) · 8-K (5) · pharmaceutical (4) · filing (3) · corporate-action (3) · acquisition (3) · 10-Q (3) · ipo (3) · sec-filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Filing Date | 2026-03-30 | Date Alumis Inc. filed the 8-K report. |
| Period of Report | 2026-03-28 | The reporting period covered by the 8-K filing. |
| Net Loss (Q3 2025) | $110.75M | Increased from $93.12M in Q3 2024 |
| Net Loss (YTD Sep 2025) | $150.39M | Improved from $199.47M in YTD Sep 2024 |
| Gain on Bargain Purchase | $187.91M | From ACELYRIN Merger, boosting YTD results |
| Total Revenue (YTD Sep 2025) | $22.12M | Zero revenue in YTD Sep 2024 |
| R&D Expenses (YTD Sep 2025) | $303.21M | Increased from $178.35M in YTD Sep 2024 |
| Cash and Cash Equivalents (Sep 30, 2025) | $65.26M | Decreased from $169.53M at Dec 31, 2024 |
| Net Cash Used in Operating Activities (YTD Sep 2025) | $297.62M | Significant cash burn |
| Weighted-Average Shares Outstanding (Q3 2025) | 104,109,243 | Increased from 53,752,223 in Q3 2024, indicating dilution |
| Net Income (Q2 2025) | $59.321M | Significant turnaround from -$56.508M loss in Q2 2024, driven by merger gain. |
| Total Revenue (H1 2025) | $20.055M | First reported revenue, including license and collaboration, compared to $0 in H1 2024. |
| R&D Expenses (H1 2025) | $205.377M | More than doubled from $90.526M in H1 2024, indicating aggressive pipeline investment. |
| G&A Expenses (H1 2025) | $56.745M | Increased significantly from $13.207M in H1 2024, reflecting operational expansion. |
| Cash & Cash Equivalents (June 30, 2025) | $151.753M | Decreased from $169.526M at Dec 31, 2024, despite merger gain. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Alumis Inc. (ALMS)?
Alumis Inc. has 34 recent SEC filings from Jun 2024 to Mar 2026, including 18 8-K, 5 10-Q, 3 SC 13D. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ALMS filings?
Across 34 filings, the sentiment breakdown is: 1 bearish, 31 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Alumis Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Alumis Inc. (ALMS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Alumis Inc.?
Key financial highlights from Alumis Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ALMS?
The investment thesis for ALMS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Alumis Inc.?
Key executives identified across Alumis Inc.'s filings include Board of Directors, Audit Committee, Abrar Hussain, James B. Tananbaum, Gregory A. Brown and 3 others.
What are the main risk factors for Alumis Inc. stock?
Of ALMS's 33 assessed filings, 2 were flagged high-risk, 16 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Alumis Inc.?
Forward guidance and predictions for Alumis Inc. are extracted from SEC filings as they are enriched.